We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
GLOBETECH PUBLISHING LLC

Download Mobile App




PET Scans Help Identify Effective Tuberculosis Drugs

By MedImaging International staff writers
Posted on 21 Dec 2014
Print article
Image: “Hot spots” of infection in a patient’s lungs before treatment (left). Disease improvement after six months of taking the drug linezolid (right) (Photo courtesy of the University of Pittsburgh).
Image: “Hot spots” of infection in a patient’s lungs before treatment (left). Disease improvement after six months of taking the drug linezolid (right) (Photo courtesy of the University of Pittsburgh).
Positron emission tomography (PET) lung imaging can reveal whether or not a treatment drug is able to eradicate tuberculosis (TB) lung infection in human and macaque studies. The new findings indicate that the animal model can effectively predict which experimental drugs have the best likelihood for success in human trials.

In 2012, an estimated 8.6 million people worldwide contracted TB, for which the first-line treatment demands taking four different drugs for six to eight months to get a durable cure, explained senior investigator JoAnne L. Flynn, PhD, professor of microbiology and molecular genetics, University of Pittsburgh (Pitt) School of Medicine (PA, USA). Patients who are not cured of the infection (approximately 500,000 per year) can develop multidrug resistant TB, and have to take as many as six drugs for two years.

The study’s findings were published online December 4, 2014, in the journal Science Translational Medicine. “Some of those people don’t get cured, either, and develop what we call extensively drug-resistant, or XDR, TB, which has a very poor prognosis,” she said. “Our challenge is to find more effective treatments that work in a shorter time period, but the standard preclinical models for testing new drugs have occasionally led to contradictory results when they are evaluated in human trials.”

In an earlier study, Dr. Flynn’s colleagues at the US National Institutes of Health (Bethesda, MD, USA) found that the drug linezolid effectively treated XDR-TB patients who had not improved with conventional treatment, even though mouse studies suggested it would have no impact on the disease. To further examine the effects of linezolid and another drug of the same class, Dr. Flynn and her NIH collaborators, led by Clifton E. Barry III, Ph.D., performed PET/computed tomography (PET/CT) scans in TB-infected humans and macaques, which also get lesions known as granulomas in the lungs. In a PET scan, a tiny amount of a radioactive probe is injected into the blood that gets captured by metabolically active cells, leaving a “hot spot” on the image.

The researchers noted that humans and macaques had very similar disease profiles, and that both groups had hot spots of TB in the lungs that in most cases improved after drug treatment. In addition, CT scans, which show anatomic detail of the lungs, indicated post-treatment improvement. One patient had a hot spot that got worse, and further testing revealed his TB strain was resistant to linezolid.

The findings show that a macaque model and PET scanning can better predict which drugs are likely to be effective in clinical trials, and that could help get new treatments to patients faster, Dr. Flynn said. The scans also could be useful as a way of confirming drug resistance, but aren’t likely to be implemented routinely. “We plan to use this PET scanning strategy to determine why some lesions don’t respond to certain drugs, and to test candidate anti-TB agents,” she said. “This might give us a way of tailoring treatment to individuals.”

Related Links:

University of Pittsburgh School of Medicine


Gold Member
Solid State Kv/Dose Multi-Sensor
AGMS-DM+
New
Breast Imaging Workstation
SecurView
MRI System
uMR 588
New
Ultrasound Software
UltraExtend NX

Print article

Channels

Radiography

view channel
:	Image: The AI model could be a valuable adjunct to human radiologists in breast cancer diagnoses and risk prediction (Photo courtesy of 123RF)

AI Model Predicts 5-Year Breast Cancer Risk from Mammograms

Approximately 13% of U.S. women, or one in every eight, are predicted to develop invasive breast cancer over their lifetime, with 1 in 39 women (3%) succumbing to the illness, according to the American... Read more

General/Advanced Imaging

view channel
Image: The CIARTIC Move self-driving mobile C-arm has received FDA clearance (Photo courtesy of Siemens)

Self-Driving Mobile C-Arm Reduces Imaging Time during Surgery

Intraoperative imaging faces significant challenges due to staff shortages and the high demands placed on surgical teams in the operating room (OR). A common challenge during many OR procedures is the... Read more

Imaging IT

view channel
Image: The new Medical Imaging Suite makes healthcare imaging data more accessible, interoperable and useful (Photo courtesy of Google Cloud)

New Google Cloud Medical Imaging Suite Makes Imaging Healthcare Data More Accessible

Medical imaging is a critical tool used to diagnose patients, and there are billions of medical images scanned globally each year. Imaging data accounts for about 90% of all healthcare data1 and, until... Read more

Industry News

view channel
Image: Samsung Medison CEO Mr. Yongkwan Kim and Bracco Imaging CEO Dr. Fulvio Renoldi Bracco endorsed a MoU agreement (Photo courtesy of Bracco Group)

Samsung and Bracco Enter Into New Diagnostic Ultrasound Technology Agreement

Samsung Medison (Seoul, South Korea) and Bracco Imaging (Milan, Italy) have entered into a Memorandum of Understanding (MoU) agreement to pioneer a new area for diagnostic ultrasound devices and contrast agents.... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.